Our study had two objectives: The first objective was to preclinically evaluate the efficacy of the [211At]At-anti-CA-IX antibody (ATO-101TM), an astatine-211-labeled anti-CA-IX antibody, in a bladder cancer cell line and ATO-101TM biodistribution in healthy mice. The gene discussed is CA9; the disease is urinary bladder carcinoma.